×
About 8,708 results

ALLMedicine™ Hypertriglyceridemia Center

Research & Reviews  2,172 results

The Park Rx trial to increase physical activity among low-income youth.
https://doi.org/10.1016/j.cct.2022.106930
Contemporary Clinical Trials; Zarr R, Han B et. al.

Oct 4th, 2022 - The Park Rx study is a prospective, randomized controlled trial implemented within a federally qualified health center serving a low-income population in Washington, DC. The 5-year randomized controlled trial will recruit 500 children, ages 6-16 t...

The beneficial effect of a comprehensive diabetes care model on high-risk relatives acc...
https://doi.org/10.1016/j.pcd.2022.09.008
Primary Care Diabetes; Garcia-Ulloa AC, Díaz-Pineda M et. al.

Oct 2nd, 2022 - Assess the effect of a diabetes program on lifestyle, metabolic, and mental health parameters in relatives of patients with T2D, and correlate changes between relatives and patients. Relatives were included in a structured program for patients wit...

Metabolic Dysregulation in Adult Survivors of Pediatric Hematopoietic Stem Cell Transpl...
https://doi.org/10.1210/clinem/dgac561
The Journal of Clinical Endocrinology and Metabolism; Vadmand AC, Nissen AA et. al.

Oct 2nd, 2022 - Survivors of pediatric hematopoietic stem cell transplantation (HSCT) have increased risk of developing metabolic syndrome (MetS), but the mechanisms are poorly understood. To test the hypothesis that insufficient secretion of glucagon-like peptid...

Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertr...
https://doi.org/10.1016/j.diabres.2022.110091
Diabetes Research and Clinical Practice; Kito K, Nomoto H et. al.

Sep 30th, 2022 - Pemafibrate, a novel selective peroxisome proliferator-activated receptor modulator, was shown to ameliorate lipid abnormalities in a phase III clinical trial of patients with type 2 diabetes mellitus (T2DM). However, its efficacy has not been dem...

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
https://clinicaltrials.gov/ct2/show/NCT05079919

Sep 29th, 2022 - This is a multi-center, randomized, double-blind, placebo-controlled study in up to approximately 540 participants. Participants will be randomized to receive olezarsen or placebo in a 53-week treatment period. The length of participation in the s...

see more →

Guidelines  3 results

Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Pro...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019936
Orphanet Journal of Rare Diseases; Mosbah H, Donadille B et. al.

Apr 21st, 2022 - Dunnigan syndrome, or Familial Partial Lipodystrophy type 2 (FPLD2; ORPHA 2348), is a rare autosomal dominant disorder due to pathogenic variants of the LMNA gene. The objective of the French National Diagnosis and Care Protocol (PNDS; Protocole N...

2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in...
https://doi.org/10.1016/j.jacc.2021.06.011
Journal of the American College of Cardiology; Virani SS, Morris PB et. al.

Aug 2nd, 2021 - 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.|2021|Virani SS,Morris PB,Agarwa...

Menopause symptom management in women with dyslipidemias: An EMAS clinical guide.
https://doi.org/10.1016/j.maturitas.2020.03.007
Maturitas Anagnostis P, Bitzer J et. al.

Mar 27th, 2020 - Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile, with an increase in the concentrations of total cholesterol (TC) and low-density lipoprotein choles...

see more →

Drugs  809 results see all →

Clinicaltrials.gov  269 results

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
https://clinicaltrials.gov/ct2/show/NCT05079919

Sep 29th, 2022 - This is a multi-center, randomized, double-blind, placebo-controlled study in up to approximately 540 participants. Participants will be randomized to receive olezarsen or placebo in a 53-week treatment period. The length of participation in the s...

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
https://clinicaltrials.gov/ct2/show/NCT05552326

Sep 26th, 2022 - This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study in up to approximately 390 participants. Participants will be randomized to receive olezarsen or placebo in a 53-week treatment period. The length of participation...

Ketamine in Acute Brain Injury Patients.
https://clinicaltrials.gov/ct2/show/NCT05097261

Sep 23rd, 2022 - In this study the effects of ketamine as an adjunct to an standard sedation regime in adult TBI patients will be investigated on the therapy intensity level and intracranial pressure. All patients will receive propofol for sedation to control ICP,...

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
https://clinicaltrials.gov/ct2/show/NCT02262832

Sep 19th, 2022 - Leptin is an adipocyte-derived hormone that can be thought of as a signal from adipose tissue to the rest of the body conveying information about long-term nutritional status. Patients with the very rare condition of generalized lipodystrophy have...

Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
https://clinicaltrials.gov/ct2/show/NCT02262806

Sep 10th, 2022 - Leptin is an adipocyte-derived hormone that can be thought of as a signal from adipose tissue to the rest of the body conveying information about long-term nutritional status. Patients with lipodystrophy have leptin deficiency secondary to lack of...

see more →

News  230 results

FDA Issues Complete Response Letter to Surufatinib for Advanced Neuroendocrine Tumors
https://www.onclive.com/view/fda-issues-complete-response-letter-to-surufatinib-for-advanced-neuroendocrine-tumors

May 2nd, 2022 - The FDA has issued a complete response letter (CRL) to the new drug application (NDA) seeking the approval of surufatinib for the treatment of patients with pancreatic and extra-pancreatic neuroendocrine tumors (NETs), according to an announcement...

High Triglycerides Up CV Risk After Atherothrombotic Stroke
https://www.medscape.com/viewarticle/970799

Mar 23rd, 2022 - Patients who have had a stroke or transient ischemic attack (TIA) of atherothrombotic origin and have high triglyceride levels are at increased risk of having further cardiovascular events, including a recurrent stroke, even if they are taking sta...

High Triglycerides: The Latest Recommendations
https://www.medscape.com/viewarticle/967496

Feb 18th, 2022 - This transcript has been edited for clarity. I'm Dr Neil Skolnik and today I'm going to talk about the American Heart Association's (AHA's) latest guidelines on the management of elevated triglycerides. This is important because even when high LDL...

Addition of Dalpiciclib to Fulvestrant Improves PFS in HR+ Advanced Breast Cancer
https://www.onclive.com/view/addition-of-dalpiciclib-to-fulvestrant-improves-pfs-in-hr-advanced-breast-cancer

Feb 14th, 2022 - The addition of dalpiciclib (SHR6390) to fulvestrant (Faslodex) significantly prolonged progression-free survival (PFS) vs fulvestrant alone in patients with hormone receptor (HR)–positive, HER2-negative advanced breast cancer, according to data f...

Lorlatinib Approved in Europe for ALK+ Advanced NSCLC
https://www.onclive.com/view/lorlatinib-approved-in-europe-for-alk-advanced-nsclc

Jan 28th, 2022 - The European Commission has granted a marketing authorization for lorlatinib (Lorviqua) for use as a single agent in the treatment of adult patients with ALK-positive advanced non–small cell lung cancer (NSCLC) who did not receive a prior ALK inhi...

see more →